The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Autoimmunity and Anti-TNF-α Agents
Abstract
Treatment of rheumatoid arthritis (RA) patients with anti-tumor necrosis factor-alpha (anti-TNF-alpha) biologic agents has been associated with a reduction in the levels of specific autoantibodies, such as rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP), and the induction of non- organ-specific autoantibodies (antinuclear antibodies [ANAs], anti-dsDNA, and antiphospholipid antibodies [aPLs]). The mechanisms by which the blockade of anti-TNF-alpha decreases the generation of specific autoantibodies, such as anti-CCP and RF, are not yet known. However, it has been shown that these agents can downregulate the production of several inflammatory cytokines and mediators and that these anti-inflammatory effects may account for reduced autoantibody generation, particularly in the synovial compartment. Infliximab treatment leads to the induction of ANAs in 63.8% of RA patients and 49.1% of Crohn's disease (CD) patients, and anti-dsDNA antibodies in 13% of RA patients and 21.5% of CD patients, respectively. The development of ANAs and anti-dsDNA antibodies has also been described after etanercept therapy in 11% and 15% of RA patients, respectively. In the controlled trials, increases in ANA and anti-dsDNA titers were observed in 5.3% and in 12.9% of adalimumab-treated RA patients. Only limited data on the induction of aPL antibodies during TNF-alpha blocking treatment are available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Cited by
Cellular and Molecular Mechanisms of Pain
Basbaum, A. I., Bautista, D. M., Scherrer, G., & Julius, D. (2009) · Cell · doi:10.1016/j.cell.2009.09.028 · Cited by 4,344
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071094 · Cited by 676
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Metadata
- Authors
- ATZENI, F., TURIEL, M., CAPSONI, F., DORIA, A., MERONI, P., & SARZI-PUTTINI, P.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 1051
- Issue
- 1
- Pages
- 559-569
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1976172421
- Cited by
- 160
- References
- 2
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoimmunity and Anti-TNF-α Agents. https://app.cochat.ai/papers/10.1196/annals.1361.100
- The paper
- ATZENI, F., TURIEL, M., CAPSONI, F., DORIA, A., MERONI, P., & SARZI-PUTTINI, P. (2005). Autoimmunity and Anti-TNF-α Agents. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1361.100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.